Oxford Biodyn Regulatory News (OBD)

14 December 2020

Oxford BioDynamics Plc

Board changes

 Oxford BioDynamics Plc (AIM: OBD), a biotechnology company developing personalised medicine tests based on 3D genomic biomarkers, announces that Matthew Wakefield is joining the board with immediate effect as Non-Executive Chairman. Matthew graduated with a degree in law and has an MBA in finance. He has spent his 27 year career in the city working in senior positions in both the fund management and investment banking industries.

Matthew started his career as a fund manager at Legal and General Plc before moving into broking at Nomura Holdings, Inc. He joined Collins Stewart Hawkpoint Limited ("Collins Stewart") in 1992 and was Head of Sales and a member of the management committee. He left Collins Stewart in 2004, after 12 years, to work for two charities, The Besom Foundation and The 999 Club. In 2011 Matthew set up the broking partnership Baden Hill LLP, where Matthew will remain as a partner and shareholder. Matthew has an in-depth knowledge of the Company having been one of the company's earliest external shareholders. Baden Hill LLP raised capital for the company at the IPO in 2016 and Matthew has acted as an advisor to the Company from the IPO to the current time. Matthew is currently interested in 468,813 Ordinary Shares in the Company 0.5% of the issued share capital.

The current Chairman and NED Dr Peter Pack has elected to step down from the Board for personal reasons having moved back to Germany.

Jon Burrows, CEO commented:

"The Board of Oxford BioDynamics would like to thank Peter for his service and contribution to the Company. During this unprecedented time, his input and guidance, both technically and commercially, has been invaluable, and we wish him every success for his future. The Directors look forward to working with Matthew to continue the development of the Company as it moves into the next stage of commercialisation and growth."

Matthew Wakefield, the new Chairman, said:

"I have been associated with the company for well over a decade and I am convinced now more than ever of the considerable potential in the EpiSwitch™ technology. I am looking forward to leading the Board as Chairman and working with Jon and the team in this next phase of the Company's growth."

-Ends-

For further details please contact:

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of 3D genomic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re-positioning programs, enabling the personalization of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.

The Company is headquartered in the UK and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit our website, www.oxfordbiodynamics.com , or follow us on Twitter or LinkedIn .

The following information is disclosed under AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies:

Matthew Wakefield has confirmed that there is no other additional information to be disclosed under Schedule 2 (g) of the AIM Rules.